Brief: Biogen Says Biologics License Application For Subcutaneous Formulation Of Leqembi For Treatment Of Early Alzheimer’S Disease Designated For Priority Review In China
Biogen forecasts upbeat annual profit, eyes 2028 launch of key drugs (updated)
Revenue Of Leqembi (Preliminary Basis)
Biogen forecasts annual profit above estimates as Leqembi sales pick up
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech (updated)
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
Brief: Shanghai Henlius Biotech Announces License Agreement With Eisai
Brief: Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai
Brief: Eisai Submits Marketing Authorisation Variation To EMA For Intravenous Maintenance Dosing With Leqembi
Brief: Eisai & Biogen Say U.S. FDA Accepts Leqembi Supplemental Biologics License Application As Subcutaneous Starting Dose For Treatment Of Early Alzheimer's Under Priority Review
Brief: Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan
Analysis: Alzheimer's drug hunt learns from cancer fight's multi-target playbook
Novo Nordisk Alzheimer's drug trials fail in blow to weight-loss giant (updated)
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials
Novo Nordisk says Alzheimer's drug trial fails, hammering shares (updated)
Biogen rises after Novo Nordisk's drug fails to meet main goal in Alzheimer's trials
Lilly becomes first drugmaker to join trillion-dollar club on weight-loss demand boom (updated)
Focus: High-stakes Novo Nordisk Alzheimer's studies could yield answers on GLP-1 benefit
Notice Of The Settlement Of Patent Infringement Litigation Related To Lenvatinib In The U.S.